All Stories

  1. The impact of preimplantation genetic testing on prenatal diagnostic procedures

    Article • The Journal of Maternal-Fetal & Neonatal Medicine, October 2019, Taylor & Francis

    David Krantz

  2. Microarray analysis: First-trimester maternal serum free β-hCG and the risk of significant copy number variants

    Article • Prenatal Diagnosis, September 2018, Wiley

    David Krantz

  3. Elevated maternal serum-free β-human chorionic gonadotropin (β-hCG) and reduced risk of spontaneous preterm delivery

    Article • The Journal of Maternal-Fetal & Neonatal Medicine, April 2018, Taylor & Francis

    David Krantz, Dr. Burton Rochelson

  4. Expanded conventional first trimester screening

    Article • Prenatal Diagnosis, July 2017, Wiley

    David Krantz, Mr David A Krantz

  5. 230: Do elevated first-trimester maternal serum alpha-fetoprotein (MSAFP) levels predict elevated second trimester levels?

    Article • American Journal of Obstetrics and Gynecology, January 2017, Elsevier

    David Krantz

  6. 331: Maternal serum free-beta human chorionic gonadotrophin (hCG) and the risk of spontaneous preterm delivery

    Article • American Journal of Obstetrics and Gynecology, January 2017, Elsevier

    David Krantz

  7. Screening for Open Neural Tube Defects

    Article • Clinics in Laboratory Medicine, June 2016, Elsevier

    David Krantz

  8. Incorporation of dried blood alpha fetoprotein into traditional first trimester Down syndrome screening service

    Article • Prenatal Diagnosis, May 2015, Wiley

    Mr David A Krantz, David Krantz

  9. [179-POS]

    Article • Pregnancy Hypertension, January 2015, Elsevier

    Mr David A Krantz, David Krantz

  10. Maternal Serum Screening Markers and Adverse Outcome: A New Perspective

    Article • Journal of Clinical Medicine, July 2014, MDPI AG

    Mr David A Krantz, David Krantz

  11. Maternal serum analytes as predictors of IUGR with different degrees of placental vascular dysfunction

    Article • Prenatal Diagnosis, April 2014, Wiley

    Mr David A Krantz, David Krantz

  12. Elevated first trimester PAPP-A is associated with increased risk of placenta accreta

    Article • Prenatal Diagnosis, December 2013, Wiley

    David Krantz

  13. Nearly a third of abnormalities found after first-trimester screening are different than expected:10-year experience from a single center

    Article • Prenatal Diagnosis, January 2013, Wiley

    David Krantz

  14. 573: Extremely high risk of fetal death and severe perinatal complications associated with simultaneously elevated AFP and very low unconjugated estriol

    Article • American Journal of Obstetrics and Gynecology, January 2013, Elsevier

    Mr David A Krantz, David Krantz

  15. 144: Second-trimester maternal serum free β-hCG is associated with discordant growth in twin gestations

    Article • American Journal of Obstetrics and Gynecology, January 2012, Elsevier

    David Krantz

  16. 143: Twin discordant birth weight may be predicted at the first-trimester aneuploidy screen

    Article • American Journal of Obstetrics and Gynecology, January 2012, Elsevier

    David Krantz

  17. OP27.02: Biochemical maternal serum markers alone and in combination predict extremes of Doppler abnormality (AREDV)

    Article • Ultrasound in Obstetrics and Gynecology, September 2011, Wiley

    David Krantz

  18. 65: First trimester screening in triplets

    Article • American Journal of Obstetrics and Gynecology, January 2011, Elsevier

    Mr David A Krantz, David Krantz

  19. 780: First trimester dried blood ADAM-12 as a marker for preterm severe pre-eclampsia (PEC) and intrauterine growth restriction (IUGR)

    Article • American Journal of Obstetrics and Gynecology, January 2011, Elsevier

    Mr David A Krantz, David Krantz

  20. 737: Sequential testing for down syndrome: the impact on estimated risk

    Article • American Journal of Obstetrics and Gynecology, January 2011, Elsevier

    David Krantz

  21. 736: First-trimester aneuploidy risk assessment: a large single institution study

    Article • American Journal of Obstetrics and Gynecology, January 2011, Elsevier

    David Krantz

  22. Does timing of biochemistry in first-trimester aneuploidy risk assessment affect the gestational age at prenatal diagnosis and pregnancy termination?

    Article • Prenatal Diagnosis, October 2010, Wiley

    David Krantz

  23. Undermeasurement of Nuchal Translucencies: Implications for Screening

    Article • Obstetrics and Gynecology, October 2010, Wolters Kluwer Health

    Mr David A Krantz, David Krantz

  24. Are second-trimester minor sonographic markers for Down syndrome useful in patients who have undergone first-trimester combined screening?

    Article • American Journal of Obstetrics and Gynecology, October 2010, Elsevier

    David Krantz

  25. Screening for Open Neural Tube Defects

    Article • Clinics in Laboratory Medicine, September 2010, Elsevier

    Mr David A Krantz, David Krantz

  26. 731: Management of the CVS window in first trimester Down syndrome screening

    Article • American Journal of Obstetrics and Gynecology, December 2009, Elsevier

    Mr David A Krantz, David Krantz

  27. 69: Are second trimester minor sonographic markers for trisomy 21 (T21) useful in patients who have undergone first trimester screening (FTS)?

    Article • American Journal of Obstetrics and Gynecology, December 2009, Elsevier

    David Krantz

  28. 108: First trimester screening with nasal bone in twins

    Article • American Journal of Obstetrics and Gynecology, December 2007, Elsevier

    Mr David A Krantz, David Krantz

  29. Genetic Sonography After First-trimester Down Syndrome Screening

    Article • Obstetrical & Gynecological Survey, September 2007, Wolters Kluwer Health

    Mr David A Krantz, David Krantz

  30. Genetic sonography after first-trimester Down syndrome screening

    Article • Ultrasound in Obstetrics and Gynecology, January 2007, Wiley

    Mr David A Krantz, David Krantz

  31. Utilization of first trimester screening is heavily skewed to higher risk patients

    Article • American Journal of Obstetrics and Gynecology, December 2006, Elsevier

    Mr David A Krantz, David Krantz

  32. First trimester down syndrome screening using early biochemistry to allow for an instant risk assessment at the conclusion of U/S exam

    Article • American Journal of Obstetrics and Gynecology, December 2006, Elsevier

    Mr David A Krantz, David Krantz

  33. Previous aneuploidy does not significantly alter 1st trimester free beta hcg and papp-a in subsequent normal pregnancies

    Article • American Journal of Obstetrics and Gynecology, December 2006, Elsevier

    Mr David A Krantz, David Krantz

  34. First-trimester maternal serum markers of fetal anomalies

    Article • September 2006, Taylor & Francis

    Mr David A Krantz, David Krantz

  35. P01.05: The effect of ethnicity on first-trimester nasal bone assessment

    Article • Ultrasound in Obstetrics and Gynecology, August 2006, Wiley

    Mr David A Krantz, David Krantz

  36. First-trimester maternal dried blood Down syndrome screening marker levels in early pregnancy loss

    Article • Prenatal Diagnosis, January 2006, Wiley

    Mr David A Krantz, David Krantz

  37. Geometric morphometric analysis of shape outlines of the normal and abnormal fetal skull using three-dimensional sonographic multiplanar display

    Article • Ultrasound in Obstetrics and Gynecology, January 2006, Wiley

    Mr David A Krantz, David Krantz

  38. Maternal weight and ethnic adjustment within a first-trimester Down syndrome and trisomy 18 screening program

    Article • Prenatal Diagnosis, January 2005, Wiley

    Mr David A Krantz, David Krantz

  39. Appropriate terminology for freeβ-hCG

    Article • Prenatal Diagnosis, September 2004, Wiley

    Mr David A Krantz, David Krantz

  40. Statistical flaw in SURUSS model

    Article • Prenatal Diagnosis, September 2004, Wiley

    Mr David A Krantz, David Krantz

  41. Low first-trimester PAPP-A identifies pregnancies requiring IUGR screening

    Article • American Journal of Obstetrics and Gynecology, December 2003, Elsevier

    David Krantz

  42. Incorporation of Inhibin-A in Second-Trimester Screening for Down Syndrome*

    Article • Obstetrics and Gynecology, August 2003, Wolters Kluwer Health

    David Krantz

  43. Combined first-trimester versus second-trimester serum screening for Down syndrome: A cost analysis

    Article • American Journal of Obstetrics and Gynecology, March 2003, Elsevier

    Mr David A Krantz, David Krantz

  44. Low first-trimester pregnancy-associated plasma protein-A and Cornelia de Lange syndrome

    Article • Prenatal Diagnosis, January 2003, Wiley

    Mr David A Krantz, David Krantz

  45. First-Trimester down syndrome screening using dried blood biochemistry and nuchal translucency

    Article • Obstetrics and Gynecology, August 2000, Wolters Kluwer Health

    David Krantz

  46. First-Trimester Down Syndrome Screening Using Dried Blood Biochemistry and Nuchal Translucency

    Article • Obstetrics and Gynecology, August 2000, Wolters Kluwer Health

    David Krantz

  47. First trimester biochemical screening for Down syndrome: free beta hCG versus intact hCG

    Article • Prenatal Diagnosis, January 2000, Wiley

    Mr David A Krantz, David Krantz

  48. Reply

    Article • American Journal of Obstetrics and Gynecology, October 1990, Elsevier

    Mr David A Krantz, David Krantz

  49. Reply

    Article • American Journal of Obstetrics and Gynecology, June 1988, Elsevier

    Mr David A Krantz, David Krantz

  50. Reply

    Article • American Journal of Obstetrics and Gynecology, September 1987, Elsevier

    Mr David A Krantz, David Krantz

  51. Maternal serum α-fetoprotein screening

    Article • American Journal of Obstetrics and Gynecology, March 1987, Elsevier

    Mr David A Krantz, David Krantz